Screen Shot 2019-06-20 at 2.30.50 PM.png
Fund.png

Solid. Experienced. Motivated.

Led by a team of cross-functional domain experts. 

EXECUTIVE TEAM

RobSarrazin.jpg

CIO & Managing Partner

Mr. Sarrazin is Chief Investment Officer and Managing Partner of the Autism Impact Fund where he oversees the firm and leads AIF’s Life Sciences practice. Rob’s career as a longtime healthcare investor, private equity partner and corporate development executive includes decades of experience overseeing a large portfolio of control investments, including corporate strategic transactions and over 30+ middle market growth acquisitions under multiple private equity funds.

  • LinkedIn
Ashok Srinivasan.jpg

An innovative and patient-oriented scientist, Ashok Srinivasan has an extensive history of leadership in clinical and basic science.

As the Translational Research Scientist for NSABP Foundation/NRG Pittsburgh, Ashok has dedicated the past seven years to translating scientific advances to clinical trials, supporting new technology and therapeutic advancements for breast and colorectal cancer. In this role, Ashok has consulted as a molecular genetics / genomics expert in developing scientific rationales for 10+ clinical trials and educated clinical trialists on emerging trends and best practices in

oncology research. 

  • LinkedIn
CRM-Headshot-7.20.20.jpg

Mr. Male is Co-Founder and Managing Partner of the Autism Impact Fund where he oversees the firm and leads the Business Services practice. Chris has over ten years experience leading venture and middle-market equity financing across business services, impact, and real estate, most recently as Managing Director of RBG Capital, LLC, his family's private investment arm.

  • LinkedIn
unnamed.png

Katie Mangialardi, Associate, invests on behalf of the firm’s Life Sciences and Life Span Services divisions, and has spent her career working at the intersection of healthcare and finance. Katie was previously an Associate at J.P.Morgan, where she worked across both Derivatives Sales and Acquisition Leveraged Finance.
 

Katie holds a B.S. in Biology of Global Health from Georgetown University, where she was a George F. Baker Scholar. She resides in New York.

  • LinkedIn

INVESTMENT ADVISORY TEAM

Sean O'Sullivan

SOSV (IndieBio, Hax)

AIF Founding LP

  • LinkedIn

Elizabeth Horn

Founder & CEO

2M, COMPASS

AIF Founding LP

  • LinkedIn

CEO & Founder, CPI

AIF Co-Founder & Executive Advisor

  • LinkedIn

Aberdare Ventures, NEA,

Forbes Midas List

President, Samsung Corporate Strategy Group

  • LinkedIn

Vice Chairman,

Mind & Life Institute

  • LinkedIn

Founder & CEO, Quartet, Accretive, The World Bank, McKinsey

  • LinkedIn

Venture Capitalist

Emergence, Moai Capital

  • LinkedIn

Partner, Athyrium,

Thomas H. Lee Partners

  • LinkedIn

CFO, Omega Therapeutics, Harvard Medical School

  • LinkedIn

“Venture capital is the accelerant that brings breakthrough technologies into markets. With millions of kids and
adults suffering from severe medical and

physiological challenges due to autism, now is

the time for the Autism Impact Fund.”

- Sean O’Sullivan, AIF Advisor & Founding LP

SCIENTIFIC ADVISORY BOARD

David Amaral.jpg

David Amaral, PhD

Director of the Autism Center of Excellence at UC Davis

StephenCurtis.jpg

Stephen Curtis, PhD

Managing Director, MPM Capital

Director of Autism Research, Arkansas Children's Hospital

Co-Founder, Mindstrong, NIH

  • LinkedIn
  • LinkedIn
  • LinkedIn
  • LinkedIn
Krishnan Nandabalan, PhD.jpg

Krishnan Nandabalan, PhD

  • LinkedIn
IanMarks.jpg

Ian Marks

Global VP Life Sciences, Salesforce, GSK, Novartis, Roche

  • LinkedIn

Alison Singer

Co-Founder & President, 

Autism Science Foundation

  • LinkedIn
LarryDerose.jpg

Larry Derose

Founder and CEO, AdvaStim, Inc.

  • LinkedIn

Bold strategy + Biology + Technology = Audacious goal achieved.